A European multidisciplinary network for the fight of HIV drug resistance
Webinar "COVID-19 and variants: is it possible to re-open the schools?"
1st April 2021 https://vimeo.com/event/832587
The marginal role of schools as a center for spreading the infection, when the necessary containment measures are adopted, is now demonstrated by most of the scientific literature. However, doubts remain in society and in the political world, especially as regards high schools and relatively to the spread of viral variants.
On the contrary, the costs of closure are not yet fully known and are still likely to be underestimated.
The webinar sponsored by EuResist Network will support the scientific discussion on these themes while involving both the civil society and the political institutions.
With the participation of scientists as Antonella D'arminio Monforte, Sara Gandini, Daniele Novara, of associations as Save the Children, AcrionAid, ForumDD, of members of the Italian Parliament and of the the Minister for Equal Opportunities and the Family Elena Bonetti.
Download the programme
Relevant research results from the CARE project
The CARE TB diagnostics group has been looking into potential novel biomarkers of successful treatment of multidrug-resistant tuberculosis. With the support of Linear Mixed Models to analyse the change of metabolites in response to TB treatment in cohorts of patients from Russia and Lithuania, we identified and further evaluated at least 2 candidate urine biomarkers of response to treatment.
The CARE TB treatment management group has been progressing towards developing a Geno2Pheno TB tool for prediction of drug-resistance profiles of Mycobacterium tuberculosis (Mtb) from whole genome sequencing (WGS) data. We trained and evaluated a variety of RF-models on different genetic features for 9 important drugs using a set of up to 2,000 Mtb WGSs. The resulting models showed overall significantly improved performance compared to a state-of-the-art mutation catalogue, including both known resistance mediating and benign mutations.
The CARE HIV epidemiology and treatment resistance group has achieved important scientific progress in the evaluation of drug resistance to integrase strand inhibitors (INSTI). A new consensus A6 sequence has been created and also a full recombinant A6 viruse has been created which is now being tested against different drugs. A high-throughput sequencing assay for HIV-1 A6 strains has been established and validated on Swedish, German and Russian samples. The sub-subtype A6 has been analyzed for its in vitro phenotypic susceptibility to INSTIs and it showed to be as susceptible as the reference subtype B to INSTIs, including dolutegravir, bictegravir, cabotegravir.
Furthermore, the CARE HIV/HCV and host genomics group has enrolled an extensive prospective cohort of over 6500 people with HIV and HIV/HCV coinfection in Georgia, Russia and Ukraine. Detailed clinical and demographical data have been collected from the region of the world where we have little data so far. An HIV cascade of care constructed for this cohort showed that the target of 90% PLHIV on ART was achieved in Georgia and Ukraine but not in Russia, and the target of 90% on those on ART having viral suppression was achieved only in Georgia.
Held with success the conference on “Joint efforts against infectious diseases: HIV, TB, HCV”
Moscow, 27th January 2020
Held with success the high level conference in Moscow at the presence of the EU ambassador in Russia Mr Ederer, of the First Deputy Minister of the Ministry of Science and Higher Education of the Russian Federation Mr Trubnikov, and of the high representative of the Ministry of Health of the Russian Federation Mr Kostennikov,
The CARE and the ARREST-TB projects presented their interim results and fuelled a lively scientific discussion in a cooperative atmosphere.
EuResist Network is accepted as member of the UN Global Compact!
EuResist Network joins the UN Global Compact, the world's largest corporate initiative based on CEO commitments to implement universal sustainability principles and to take steps to support UN goals. See the Italian participants.
The CARE project publishes its first results
In only ten months of activity the CARE partners created a solid ethics permissions, data and samples sharing infrastructure for a wide network of collaboration against HIV, TB and HCV. Already three papers have been published on HIV-1 resistance and epidemiology and one poster presented at EACS 2019!The CARE project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.
INTEGRATE at EACS 2019
The INTEGRATE project results have been presented at. EACS 2019, in Basel on November 6-9 2019, with an oral talk entitled "Prevalence of InSTI resistance and effectiveness of InSTI based regimens in HIV infected patients: results from a European cohort" (B. Brossetti et al.). The presentation will take place on Thursday, November 7th 2019 during the session "Basic and translational HIV biology" (14:00-16:00).
The project has been supported by an unrestricted grant from Gilead Sciences.
Data from over 103, 000 HIV patients in EIDB
The EIDB, expanded to collect clinical and resistance information, contains now data from over 103, 000 HIV patients, The DB is always available for HIV research studies, subject to approval by the Scientific Board. If you are interested to submit a study please contact us.
PhD fellowship on HIV molecular epidemiology
A PhD fellowship on HIV molecular epidemiology has been funded by the EuResist Network at the PhD programme in Data Science of Sapienza University of Rome. The PhD in Data Science of Sapienza is a multidisciplinary doctoral program coordinated by the Department of Computer, Control and Management Engineering "Antonio Ruberti".
The student supported by the fellowship, who has already been selected, will focus on epidemiology of subtype A in the EuResist Integrated DataBase.
Two posters from the EuResist Mentor School presented at EACS 2019
The two studies: “A retrospective analysis of the EuResist data set assessing dual therapy success in a real-life context” and “A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone” have been realized by the participants of the EMS 2018 under guidance of the trainer M. Bohm and of EuResist Network mentors.
The project has been supported by Janssen Parmaceutical and Gilead Sciences.
EuResist at the PROHIV 2019 international conference on HIV and AIDS, Moscow 23-24 September 2019
EuResist will be present with a talk entitled "The EuResist Integrated DataBase: how to exploit real life data for the study of HIV drug resistance" at the PROHIV 2019 international conference on HIV and AIDS to be held in Moscow on September 23-24 2019.
Two abstracts from the EMS at the 17th European Meeting on HIV & Hepatitis May 2019
Two studies realised by the students of the EuResist Mentor School under the guidance of the tutors will be presented as posters at the European HIV & Hep Meeting in Rome 22-24 May 2019.
EuResist at the AREVIR meeting 3-4 May 2019
EuResist recent results will be presented in the EuResist session within the annual AREVIR meeting in Cologne 3-4 May 2019.
The CARE project breakes the news
The kick-off of the CARE project held in Rome on Jan 23 and 24 raised the interest of the press.
Read the Sole 24 ore sanità!
About EuResist Network
EuResist Network is an international non-profit partnership devoted to understanding and fighting the resistance to anti-HIV drugs.
Its approach is eminentely multidisciplinary and focused on exploiting the power of real world data at the benefit of the individual patient.
EuResist Network manages:
the EuResist Integrated Data Base (EIDB), among the largest available databases of HIV genotypes and clinical response to antiretroviral therapy, with more than 96.000 patients. The EIDB is open for research studies.
Reasearch projects on HIV and other infectious diseases.. EuResist Network is actively involved in front end research to combat HIV drug resistance and the spread of HIV and other infectious diseases. It coordinates and participates in several research projects, including EU funded projects.
Training activities on HIV drug resistance and data management. EuResist Network organises on-site and distant courses and offers training material on drug resistance and drug resistance data management.
The EuResist prediction engine, a data-driven system which predicts the response to combination drug therapy for a patient with a given viral genotype. The engine has an overall accuracy of around 77% which compares favourably with existing rules-based state-of-the-art systems such as HIVdb, ANRS, REGA.
The EuResist Satellite DB (EsaDB), a tool for management of HIV patients data running locally on a PC. ESaDB is provided for free.
Webinar "COVID-19 and variants: is it possible to re-open the schools?"
1st April 2021 - The webinar sponsored by EuResist Network supports the scientific discussion on the marginal role of schools as a center for spreading the infection, the necessary containment measures and the costs of closure.
At Jan 2020 the number of INSTI containing therapies in the EIDB is >38000 and the number of TCEs is >5700
The CARE project publishes its first results!
In only ten months of activity, three papers have been published on HIV-1 resistance and epidemiology and one poster presented at EACS 2019!
Held in Rome on 23-24 Jan 2019 the kick-off of the CARE H2020 project
10 years of EURESISTANCE!
2009-2019: EuResist turns ten years old!
CARE (Common Action against HIV/TB/HCV across the Regions of Europe) aims at analysing and addressing the human immunodeficiency virus (HIV), tuberculosis (TB) and hepatitis C (HCV) epidemics across Europe and Russia, by establishing new networks and consolidating previous cooperative actions between the European Union and the Russian Federation.
Project coordinator F. Incardona (EuResist Network) Scientific coordinator J. Lundgren (CHIP/RegionH).
Funding received from the EU’s H2020 research and innovation programme under g.a N. 825673
The INTEGRATE project aims at building and maintaining a large, curated collection of virological and clinical data to increase scientific knowledge on resistance to integrase strand transfer inhibitors (InSTI) and on the most appropriate use of this class of antiretroviral agents.
EuResist Network organises the EuResist Mentor School (EMS) an innovative educational project finalised to train young physicians and biologists in dealing with structured data (databases).
The EMS 2018 has been successfully held in Cologne
EuResist Network participates in the pilot project for the realization of a System of Health Monitoring and Surveillance activities in the Autonomous Region of Kurdistan...
EucoHIV is an independent self-constituted study group aiming at increasing scientific knowledge on HIV coreceptor usage and its clinical significance, including...
The EuResist Network is open to new partners of proved or potential scientific value for expanding both database and scientific programme. Co-operation with developing countries with high rates of HIV infections is mostly welcome.
All the partners have one representative in the EuResist Network Scientific Board. The Board evaluates requests to access the EIDB for scientific studies. Partner's activities and data are protected by the data and authorship policy.
On Feb 4th 2019, our great friend and EuResister Andrea De Luca lost his life in a horrible car accident, at the age of 55.
One year has passed and still we miss him with incredulity and sorrow.
Among many other projects, Andrea joined EuResist as a key leader soon after its launch, devoting his energy, commitment and capability to the success of the Network. He was an extra lively, smart, passionate, and positive person, always ready to help and take new tasks.
His loss is a huge loss for us, for his patients, for his beloved ones, for the international research community.
Ciao Andrea, we'll always miss you.